BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2155684)

  • 1. Regional central serotonin-2 receptor binding and phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions.
    Butler PD; Pranzatelli MR; Barkai AI
    Brain Res Bull; 1990 Jan; 24(1):125-9. PubMed ID: 2155684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic ACTH treatment: influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions.
    Pranzatelli MR; Eng B
    Peptides; 1989; 10(1):5-8. PubMed ID: 2546129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional significance of neonatal 5,7-dihydroxytryptamine lesions in the rat: response to selective 5-HT1A and 5-HT2,1C agonists.
    Pranzatelli MR; Dollison AM; Huang YY
    Brain Res Bull; 1990 Jun; 24(6):747-53. PubMed ID: 2142615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brainstem serotonergic hyperinnervation modifies behavioral supersensitivity to 5-hydroxytryptophan in the rat.
    Pranzatelli MR; Huang YY; Dollison AM; Stanley M
    Brain Res Dev Brain Res; 1989 Nov; 50(1):89-99. PubMed ID: 2582610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High and low affinity 5-HT2 and 5-HT1C binding sites: responses to neonatal 5,7-DHT lesions in rat brain.
    Pranzatelli MR; Gregory CM
    Cytobios; 1993; 75(302-303):197-209. PubMed ID: 8243108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography.
    Fischette CT; Nock B; Renner K
    Brain Res; 1987 Sep; 421(1-2):263-79. PubMed ID: 3690273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracisternal 5,7-dihydroxytryptamine lesions in neonatal and adult rats: comparison of response to 5-hydroxytryptophan.
    Pranzatelli MR; Dollison AM; Hlibczuk V
    Dev Neurosci; 1989; 11(3):205-11. PubMed ID: 2788568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin-lesion myoclonic syndromes. I. Neurochemical profile and S-1 receptor binding.
    Pranzatelli MR; Rubin G; Snodgrass SR
    Brain Res; 1986 Jan; 364(1):57-66. PubMed ID: 3484992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced selective 5-HT depletions in the DHT rat model: denervation supersensitivity and recovery of function.
    Pranzatelli MR; Snodgrass SR
    Psychopharmacology (Berl); 1986; 89(4):449-55. PubMed ID: 3092275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations.
    Pranzatelli MR; Snodgrass SR
    Brain Res; 1986 Jan; 364(1):67-76. PubMed ID: 3484993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p,p'-DDT myoclonic/epileptic model: serotonin receptor binding and behavioral studies in the rat.
    Pranzatelli MR; Tailor PT; Pluchino R; Gonzales W; Simmens S
    Neurotoxicology; 1994; 15(2):261-72. PubMed ID: 7991214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal 5,7-DHT lesions upregulate [3H]mesulergine-labelled spinal 5-HT1C binding sites in the rat.
    Pranzatelli MR
    Brain Res Bull; 1990 Jul; 25(1):151-3. PubMed ID: 2207701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site.
    Conn PJ; Sanders-Bush E
    J Neurosci; 1986 Dec; 6(12):3669-75. PubMed ID: 3025382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The guinea pig myoclonic model: behavioral supersensitivity to 5-hydroxytryptophan induced by intracisternal 5,7-dihydroxytryptamine.
    Pranzatelli MR; Snodgrass SR
    Eur J Pharmacol; 1987 Nov; 143(2):237-42. PubMed ID: 3500866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective destruction of the serotonergic fibers of the fornix-fimbria and cingulum bundle increases 5-HT1 but not 5-HT2 receptors in rat midbrain.
    Quik M; Azmitia E
    Eur J Pharmacol; 1983 Jun; 90(4):377-84. PubMed ID: 6884427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behavior in rats.
    Kuhn CM; Vogel RA; Mailman RB; Mueller RA; Schanberg SM; Breese GR
    Psychopharmacology (Berl); 1981; 73(2):188-93. PubMed ID: 6785814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in the mouse cortex has pharmacological characteristics compatible with mediation via 5-HT2 receptors but this response does not reflect altered 5-HT2 function after 5,7-dihydroxytryptamine lesioning or repeated antidepressant treatments.
    Godfrey PP; McClue SJ; Young MM; Heal DJ
    J Neurochem; 1988 Mar; 50(3):730-8. PubMed ID: 2828545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imipramine and serotonin-2 agonists and antagonists on serotonin-2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation.
    Eison AS; Eison MS; Yocca FD; Gianutsos G
    Life Sci; 1989; 44(19):1419-27. PubMed ID: 2785627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions.
    Conn PJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1985 Jul; 234(1):195-203. PubMed ID: 2989504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
    Nabeshima T; Yamaguchi K; Ishikawa K; Furukawa H; Kameyama T
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1139-46. PubMed ID: 2826756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.